N-Acetyl Semax Amidate

Like taking a car that was only ever road-tested in one country, swapping the engine for an experimental one that's never been started, and assuming the new version drives even better — the upgrade is plausible on paper, but nobody has actually turned the key.

Semax derives from the ACTH(4-10) fragment but lacks the hormone's steroid-stimulating activity. In animal and in-vitro work it rapidly raises brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, increases nerve growth factor (NGF), and inhibits the enzymes that break down enkephalins, which may prolong endogenous opioid and regulatory-peptide signalling. It also appears to modulate dopamine and serotonin systems. The N-acetyl and amidate modifications in NASA are intended to protect the peptide from being chopped up by the body's peptidases, lengthening its half-life and improving brain penetration. This proposed mechanism is inferred from the parent compound and from chemistry; it has not been confirmed for NASA itself.

Research contexts. Not proven uses, and not recommendations.

There are no published human trials of N-Acetyl Semax Amidate itself — every claim made for it borrows from the parent compound Semax. Semax's own human evidence is limited and comes almost entirely from Russia, where it has been a registered drug since the 1990s. Reported studies include small randomised work suggesting improved attention and short-term memory in healthy volunteers, and trials in acute ischaemic stroke reporting faster neurological recovery when given intranasally early after onset. A 2018 resting-state fMRI study in healthy volunteers (PMID 30225715) did show measurable changes in default-mode-network activity after intranasal Semax versus placebo, confirming it does something to the brain — but that is a mechanistic readout, not proof of clinical benefit. Most of this literature is Russian-language, small, and not replicated to Western regulatory standards. The bottom line: the modified NASA molecule is essentially untested in people.

• !No human safety or efficacy data on the acetylated/amidated analogue specifically — you are first-in-line.
• !Sold as an unlicensed 'research chemical'; purity, dose and even correct identity are unverified and unregulated in the UK.
• !Most supporting human data is for a different (parent) molecule, is Russian-language, small, and methodologically weak.
• !Long-term effects of chronically raising BDNF and manipulating neurotrophin and opioid-peptide systems in healthy people are unknown.
• !Intranasal self-administration of grey-market peptides carries contamination and dosing-error risks.
• !Marketed online with confident nootropic claims that outrun the actual evidence.

N-Acetyl Semax Amidate is not a licensed medicine in the UK and has not been authorised or assessed by the MHRA. Neither it nor Semax holds a UK marketing authorisation. Sold as an unlicensed "research chemical," it cannot lawfully be marketed or supplied for human use as a medicine under the Human Medicines Regulations 2012; products are typically labelled "not for human consumption" to sidestep this. It is not a controlled drug, but buying it does not make self-administration safe or legal in any medicinal sense — there is no regulated product, no quality assurance and no clinical oversight.

• · None found

  No registered or completed clinical trials of N-Acetyl Semax Amidate (NASA) could be identified

  Human trial activity, where it exists, concerns the parent compound Semax, largely conducted in Russia and reported in Russian-language literature.

1. 01
   Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus — Dolotov OV, Karpenko EA, Inozemtseva LS, et al., Brain Research (2006)

   Animal mechanistic study showing Semax raises hippocampal BDNF and TrkB phosphorylation — the basis for the BDNF claims; not human, and on the parent compound.

2. 02
   Semax and selank inhibit the enkephalin-degrading enzymes from human serum — Kost NV, Sokolov OIu, Gabaeva MV, et al., Bioorganicheskaia Khimiia (2001)

   In-vitro evidence that Semax inhibits enkephalin-degrading enzymes (IC50 ~10 microM), a proposed mechanism.

3. 03
   Effects of Semax on the Default Mode Network of the Brain — Lebedeva IS, Panikratova YaR, Sokolov OYu, et al., Bulletin of Experimental Biology and Medicine (2018)

   Small resting-state fMRI study in healthy volunteers showing intranasal Semax alters default-mode-network activity vs placebo — mechanistic, not a clinical efficacy trial, and on the parent compound.

4. 04
   Semax (Wikipedia overview: structure, mechanism, Russian regulatory status)

   Background on the parent compound's ACTH(4-10) origin and registration as a drug in Russia.

5. 05
   PubMed search: N-acetyl Semax amidate human evidence

   Search returns no human clinical trials specific to the acetylated/amidated analogue, confirming the absence of NASA-specific data.